![[SIGN thistle header]](../../../../images/page-header-template.jpg)
|
|
Guideline topic: Pharmacological management of asthma
|
||||||||
| Author |
Year |
Study type |
Quality rating |
Population |
Outomes measured |
Effect size |
Confidence intervals / p values |
Comments |
|
| Magnussen |
1988 |
Randomised, double-blind, placebo-controlled, cross-over. IV aminophylline 200-351mg vs placebo. |
++ |
11 adults with asthma, aged 16-33 years |
Exercise-induced bronchoconstriction Protection index: |
(for the different preparations of aminophylline) TE 200: 0.61 TE 351: 0.82 TPD: 0.65 |
p< 0.01 p< 0.01 p< 0.01 |
A bolus of IV aminophyline significantly attenuated against EIA. Caution needed to extrapolate to oral dosing. |
|
| Phillips |
1981 |
Randomised, double-blind, placebo controlled, cross-over. 1 week treatment with oral aminophyline or placebo |
++ |
9 adults with asthma, aged 18-35 years |
Exercise-induced bronchoconstriction 4h % fall in PEF 8h % fall in PEF |
Placebo vs aminophylline: 30% vs 13% 29% vs 10% |
p< 0.01 p< 0.05 |
Oral aminophylline for 1 week significantly attenuated EIA compared to placebo. |
|
1. Magnussen H, Reuss G, Jorres R.
Methylxanthines inhibit exercise-induced bronchoconstriction at low serum theophylline
concentration and in a dose-dependent fashion. J Allergy Clin Immunol 1988;81(3):531-7.
2. Phillips MJ, Ollier S, Trembath PW, Boobis SW, Davies RJ. The effect of sustained-release
aminophylline on exercise-induced asthma. Br J Dis Chest 1981;75(2):181-9.